

## Figure 1. Warfarin Dose Reminder Chart

Name: \_\_\_\_\_ Date of adjustment: \_\_\_\_/\_\_\_\_/\_\_\_\_

Your doctor has highlighted a row below showing the total amount of warfarin (Coumadin) you should take each week. Look at the highlighted row and find the number under today's day of the week. Take that number of 5-mg warfarin tablets at approximately 5 p.m.

### Number of 5-mg tablets to take on each day of the week

Total weekly dose (mg)	Number of tablets on Monday	Number of tablets of Tuesday	Number of tablets on Wednesday	Number of tablets on Thursday	Number of tablets on Friday	Number of tablets on Saturday	Number of tablets on Sunday
2.5	1/2	0	0	0	0	0	0
5.0	1/2	0	0	0	1/2	0	0
7.5	1/2	0	1/2	0	1/2	0	0
10.0	1/2	0	1/2	0	1/2	0	1/2
12.5	1/2	0	1/2	0	1/2	1/2	1/2
15.0	1/2	0	1/2	1/2	1/2	1/2	1/2
17.5	1/2	1/2	1/2	1/2	1/2	1/2	1/2
20.0	1	1/2	1/2	1/2	1/2	1/2	1/2
22.5	1	1/2	1/2	1/2	1	1/2	1/2
25.0	1	1/2	1	1/2	1	1/2	1/2
27.5	1/2	1	1/2	1	1/2	1	1
30.0	1/2	1	1	1	1/2	1	1
32.5	1/2	1	1	1	1	1	1
35.0	1	1	1	1	1	1	1
37.5	1 1/2	1	1	1	1	1	1
40.0	1 1/2	1	1	1	1 1/2	1	1
42.5	1 1/2	1	1 1/2	1	1 1/2	1	1
45.0	1	1 1/2	1	1 1/2	1	1 1/2	1 1/2
47.5	1	1 1/2	1 1/2	1 1/2	1	1 1/2	1 1/2
50.0	1	1 1/2	1 1/2	1 1/2	1 1/2	1 1/2	1 1/2
52.5	1 1/2	1 1/2	1 1/2	1 1/2	1 1/2	1 1/2	1 1/2
55.0	2	1 1/2	1 1/2	1 1/2	1 1/2	1 1/2	1 1/2
57.5	2	1 1/2	1 1/2	1 1/2	2	1 1/2	1 1/2
60.0	2	1 1/2	2	1 1/2	2	1 1/2	1 1/2
62.5	1 1/2	2	1 1/2	2	1 1/2	2	2
65.0	1 1/2	2	2	2	1 1/2	2	2
67.5	1 1/2	2	2	2	2	2	2
70.0	2	2	2	2	2	2	2

NOTE TO THE PHYSICIAN: The initial total weekly dose (first column) can be derived using the nomogram published in: Ebell MH. Evidence-based initiation of warfarin (Coumadin). *Am Fam Physician* 2005;71:763-5; available online at: <http://www.aafp.org/afp/20050215/poc.html>.

Chart developed by Mark H. Ebell, MD, MS, Michigan State University College of Human Medicine, East Lansing. Copyright © 2005 American Academy of Family Physicians. Physicians may photocopy or adapt for use in their own practices; all other rights reserved. "Point-of-care Guides." Ebell MH. *American Family Physician*. May 15, 2005;71:1979-82. Accessible online at: <http://www.aafp.org/afp/20050515/pocform.html>.

- treatment compared with primary care management. *J Clin Pathol* 2002;55:845-9.
5. Ansell J, Holden A, Knapić N. Patient self-management of oral anticoagulation guided by capillary (fingerstick) whole blood prothrombin times. *Arch Intern Med* 1989;149:2509-11.
  6. Dalere GM, Coleman RW, Lum BL. A graphic nomogram for warfarin dosage adjustment. *Pharmacotherapy* 1999;19:461-7. day, and one and one half 5-mg tablets on Monday and Friday). Her INR today is 3.6. Looking back, her INR trend was gradually upward; her last value was 2.9. How should you adjust her warfarin dose?



## Outpatient Anticoagulation Flowsheet (continued)

### Anticoagulation Decision Support

Indication	Target INR	Duration of therapy	SORT
<b>DVT or PE<sup>1</sup></b>			
First episode, transient risk factor	2.0 to 3.0	3 months	A
First episode, idiopathic DVT	2.0 to 3.0	6 to 12 months*	A
First episode, patient with cancer	2.0 to 3.0	LMWH for 3 to 6 months, then warfarin (Coumadin); treat until cancer is resolved*	A
First episode and single risk factor†	2.0 to 3.0	6 to 12 months*	A
First episode, antiphospholipid antibodies or at least two risk factors†	2.0 to 3.0	12 months*	B
Recurrent DVT	2.0 to 3.0	Indefinitely	B
<b>Atrial fibrillation<sup>2</sup></b>	2.0 to 3.0	Indefinitely‡	A
<b>Valvular disease<sup>3</sup></b>			
Rheumatic mitral valve and atrial fibrillation or previous emboli	2.0 to 3.0	Indefinitely	B
Rheumatic mitral valve disease, normal sinus rhythm, and left atrial diameter > 5.5 cm	2.0 to 3.0	Indefinitely	B
Aortic St. Jude Medical bileaflet valve	2.0 to 3.0	Indefinitely	A
Mitral tilting disk valves and bileaflet mechanical valves	2.5 to 3.5	Indefinitely	B
Aortic CarboMedics bileaflet or Medtronic Hall tilting disk valves, normal sinus rhythm, and no LAE	2.0 to 3.0	Indefinitely	B
Mechanical valves with risk factors (atrial fibrillation, myocardial infarction, LAE, endocardial damage, low ejection fraction)	2.5 to 3.5	Indefinitely,* low-dose aspirin	B
Caged ball or disk valve	2.5 to 3.5	Indefinitely,* low-dose aspirin	B
Mechanical valve with breakthrough embolism despite INR 2.0 to 3.0	2.5 to 3.5	Indefinitely,* low-dose aspirin	B
Bioprosthetic valve (mitral)	2.0 to 3.0	3 months after placement	B
Bioprosthetic valve (aortic)	2.0 to 3.0	3 months of warfarin or aspirin	B

#### Management of Significantly Elevated INR With or Without Bleeding<sup>4</sup>

INR 5.0 to 8.9, no significant bleeding: Omit 1 to 2 doses; reduce dose 10 to 20 percent; monitor frequently. Alternatively consider vitamin K1 1.0 to 2.5 mg orally.

INR ≥ 9.0, no significant bleeding: Hold warfarin therapy; give vitamin K1 5.0 to 10 mg orally; monitor frequently. Resume at lower dose when INR is therapeutic.

Serious bleeding, any INR: Hold warfarin; give vitamin K1 10 mg slow IV plus fresh plasma or prothrombin complex concentrate, depending on urgency; repeat vitamin K1 every 12 hours as needed.

Life-threatening bleeding, any INR: Hold warfarin; give prothrombin complex concentrate (or recombinant factor VIIa as an alternative) supplemented with vitamin K1 (10 mg slow IV); repeat as needed.

INR = International Normalized Ratio; SORT = Strength-of-Recommendation Taxonomy; DVT = deep venous thrombosis; PE = pulmonary embolism; LMWH = low-molecular-weight heparin; LAE = left atrial enlargement; IV = intravenous.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, opinion, or case series.

\*—Consider indefinite therapy for selected patients.

†—Deficiency of antithrombin III, protein C, or protein S; prothrombotic gene mutation such as V Leiden or prothrombin 20210; homocystinemia, or factor VIII levels above the 90th percentile of normal; or persistent residual thrombosis on repeated testing with compression ultrasonography.

‡—Not indicated in patients younger than 65 years who do not have risk factors (i.e., heart failure, hypertension, previous ischemic stroke or transient ischemic attack, or diabetes mellitus).

1. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [published correction appears in *Chest* 2005;127:416]. *Chest* 2004;126(3 suppl):401S-428S.

2. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126(3 suppl):429S-456S.

3. Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N, et al. Antithrombotic therapy in valvular heart disease—native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126(3 suppl):457S-482S.

4. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [published correction appears in *Chest* 2005;127:415-6]. *Chest* 2004;126(3 suppl):204S-233S.